73 results returned.
Page   of  5

Community Hospitals and Wellness Centers v. State of Ohio
District Court: Common Pleas Court of Williams County    Status: Decided
Ohio’s Healthcare Price Transparency Law, passed in June 2015 (HB 52) by the Ohio Legislature, has been challenged by health care providers arguing that the …
Pharmaceutical Care Management Association (PCMA) v. Mulready
District Court: District Court of Western District of Oklahoma    Status: Pending
The 2019 Oklahoma law, Patient’s Right to Pharmacy Choice Act, targets PBM conflict of interest by prohibiting higher reimbursement rates for PBM-owned pharmacies and bans …
Pennsylvania Professional Liability Joint Underwriting Association v. Wolf
District Court: U.S. District Court, M.D. Pennsylvania    Status: Decided

State of Ohio v. OptumRx
District Court: Ohio Court of Common Pleas (Franklin County)    Status: Pending
On March 15, 2019, Ohio’s attorney general Dave Yost sued OptumRx in Ohio state court, claiming that between 2015 and 2018, the PBM failed to pass …
Texas et al. v. United States of America et al.
District Court: Northern District of Texas    Status: Pending
[Consolidated with California et al. v. Texas et al. for Supreme Court review] This case arises out of the Supreme Court’s decision in NFIB v. …
Pharm. Care Mgmt. Ass’n v. Gerhart
District Court: Southern District of Iowa    Status: Decided
Trade association representing pharmacy benefits managers (PBM) brought action against State of Iowa, seeking declaration that statute that regulated how PBMs established generic drug pricing …
Pharm. Care Mgmt. Ass’n v. Tufte
District Court: District of North Dakota    Status: Pending
Trade association representing pharmacy benefit managers (PBMs) brought action against North Dakota state officials in their official capacities, alleging that Employee Retirement Income Security Act …
Minnesota v. Sanofi-Aventis U.S. LLC
District Court: District Court of New Jersey    Status: Pending
Minnesota’s attorney general filed a suit accusing Sanofi, Eli Lilly, and Novo Nordisk, the three largest manufacturers of insulin, of price gouging. The lawsuit, filed in …
Commonwealth of Pennsylvania v. UPMC et al.
District Court: Commonwealth Court of Pennsylvania    Status: Pending
In February 2019, Pennsylvania Attorney General Josh Shapiro stepped in to intervene in the long-standing battle over market share between University of Pittsburgh Medical Center (UPMC) and …
People of the State of California ex rel. Xavier Becerra v. Sutter Health
District Court: Superior Court of California, County of San Francisco    Status: Decided
On March 29, 2018, California’s attorney general filed an antitrust and unfair competition lawsuit against Sutter Health alleging that Sutter engaged in “all-or-nothing” contracts with …
In re: Flonase Antitrust Litigation
District Court: Eastern District of Pennsylvania    Status: Pending
On December 22, 2017, the U.S. Court of Appeals for the Third Circuit ruled that an antitrust suit filed by Louisiana’s Attorney General against GlaxoSmithKline …
Mohr-Lercara v. Oxford Health Ins., Inc.
District Court: Southern District of New York    Status: Pending
A proposed class action was filed in New York federal court accusing Oxford Health Insurance of overcharging patients for prescription drugs. The complaint alleges that …
In Re UnitedHealth Group PBM Litigation
District Court: District of Minnesota    Status: Decided
Plan members brought suit against UnitedHealth Group, Inc. under ERISA and RICO for Defendants’ conduct in administrating pharmacy benefits that allegedly caused Plaintiffs to overpay …
Negron v. Cigna and OptumRx
District Court: District of Connecticut    Status: Pending
Cigna faces a class-action lawsuit alleging the insurance giant overcharged its members by more than 10 times the amount the insurer paid for certain prescription …
Federal Trade Commission v. Actavis, Inc.
District Court: Northern District of Georgia    Status: Decided
The Supreme Court ruled in favor of the FTC, holding that a brand name manufacturer’s payment to a generic competitor to settle patent infringement claims …
Federal Trade Commission v. Allergan and Watson Laboratories, Inc. et al.
District Court: Northern District of California    Status: Decided
On January 23, 2017, the FTC refiled a complaint against Watson Laboratories and its former parent company, Allergan, for entering a pay-for-delay settlement with EndoPharmaceuticals to block a generic version of …
73 results returned.
Page   of  5